UK firm Cancer Research Technology, the University of Manchester and Anglo-Swedish drug major AstraZeneca have entered into an R&D collaboration which will focus on the identification of pharmacological biomarkers in a variety of oncology indications.
The group said that, under the terms of the accord, two clinical pharmacology research fellowships will be established, which will be jointly funded by the charity Cancer Research UK and AstraZeneca. The three-year fellowship program will aim to identify and validate circulating biomarkers for use in conjunction with targeted cancer therapies.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze